Glaxo Shows What Not To Do

Quoted: James Stein, director of preventative cardiology at the University of Wisconsin-Madison, says Avandia has no proven benefits over other medicines. “Removal of this drug from the market is long overdue,” Stein says. “It does not do the public any good to have it around.” Actos, from Takeda, lowers blood sugar equally well without the heart risk, he says. Avandia sales have dropped from a peak of $3.6 billion to $1.2 billion.